Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Kezar Life Sciences ( (KZR) ).
On October 20, 2025, Kezar Life Sciences, Inc. fully repaid $6.3 million under its Loan and Security Agreement with Oxford Finance LLC, effectively terminating the agreement and releasing all associated liens and security interests. This financial move reflects the company’s strategic efforts to manage its debt obligations and potentially improve its financial standing within the industry.
The most recent analyst rating on (KZR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Kezar Life Sciences stock, see the KZR Stock Forecast page.
Spark’s Take on KZR Stock
According to Spark, TipRanks’ AI Analyst, KZR is a Neutral.
Kezar Life Sciences faces significant challenges typical of early-stage biotech companies, with no revenue and ongoing losses. While the balance sheet shows stability, the company is reliant on external funding. Technical indicators suggest negative momentum, and the valuation metrics are unattractive due to negative earnings. The lack of earnings call and corporate events data further impacts the assessment.
To see Spark’s full report on KZR stock, click here.
More about Kezar Life Sciences
Kezar Life Sciences, Inc. operates in the biotechnology industry, focusing on the development of novel small molecule therapeutics for autoimmune diseases and cancer.
Average Trading Volume: 167,133
Technical Sentiment Signal: Buy
Current Market Cap: $46.21M
For detailed information about KZR stock, go to TipRanks’ Stock Analysis page.